<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHYLPHENIDATE HYDROCHLORIDE</span><br/>(meth-ill-fen'i-date)<br/><span class="topboxtradename">Concerta, </span><span class="topboxtradename">Metadate CD, </span><span class="topboxtradename">Metadate ER, </span><span class="topboxtradename"> Methylin, </span><span class="topboxtradename"> Methylin ER, Ritalin, </span><span class="topboxtradename">Ritalin LA, </span><span class="topboxtradename">Ritalin SR<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">cerebral stimulant</span><br/><b>Prototype: </b>Amphetamine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg tablets; 2.5 mg, 5 mg, 10 mg chewable tablets; 5 mg/5 mL, 10 mg/5 mL oral solution; 10 mg, 20 mg, 30 mg, 40 mg sustained release capsules; 10 mg, 18 mg, 20 mg, 27 mg, 36 mg, 54 mg sustained release tablet</p>
<h1><a name="action">Actions</a></h1>
<p>Piperidine derivative with actions and abuse potential qualitatively similar to those of amphetamine. Acts mainly on cerebral
         cortex exerting a stimulant effect.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Results in mild CNS and respiratory stimulation with potency intermediate between amphetamine and caffeine. More prominent
         on mental than on motor activities. Also believed to have an anorexiant effect.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy in hyperkinetic syndromes characterized by attention deficit disorder, narcolepsy, mild depression, and
         apathetic or withdrawn senile behavior.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to drug; history of marked anxiety, agitation; motor tics or Tourette's disease; substance abuse; severe
         anxiety, psychosis, major depression, suicidal ideation; glaucoma; pregnancy (category C), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Alcoholic; emotionally unstable patient; abrupt discontinuation; recent MI, anxiety, cardiac arrhythmias, cardiac disease,
         dysphagia, older adults; esophageal stricture, GI obstruction, heart failure, hepatic disease, hyperthyroidism, history of
         paralytic ileus, cystic fibrosis, mania, radiographic contrast administration, seizure disorder, hypertension; history of
         seizures.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Narcolepsy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg b.i.d. or t.i.d. 3045 min p.c. (range: 2040 mg/d)<br/><br/><span class="indicationtitle">Attention Deficit Disorder</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 510 mg before breakfast and lunch, with a gradual increase of 510 mg/wk as needed (max: 60 mg/d) or 2040
               mg sustained release q.d. before breakfast (max dose: 72 mg q.d.)<br/><br/><span class="indicationtitle">Depression</span><br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 2.5 mg in morning before 9 a.m., may increase by 2.55 mg q23d (max: 20 mg/d) divided 7 a.m. and noon<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 3045 min before meals. To avoid insomnia, give last dose before 6 p.m.</li>
<li>Ensure that sustained-release form is not chewed or crushed. It must be swallowed whole.</li>
<li>Can open Metadate CD capsules and sprinkle on food</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, drowsiness, <span class="speceff-common">nervousness, insomnia.</span>
<span class="typehead">CV:</span> Palpitations, changes in BP and pulse rate, angina, cardiac arrhythmias, exacerbation of underlying CV conditions. <span class="typehead">Special Senses:</span> Difficulty with accommodation, blurred vision. <span class="typehead">GI:</span> Dry throat, anorexia, nausea; <small>HEPATOTOXICITY</small>; abdominal pain. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions (rash, fever, arthralgia, urticaria, <span class="speceff-life">exfoliative dermatitis</span>, erythema multiforme); long-term growth suppression. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">mao inhibitors</span> may cause hypertensive crisis; antagonizes hypotensive effects of <b>guanethidine,</b>
<b>bretylium;</b> potentiates action of <span class="classification">cns stimulants</span> (e.g. <b>amphetamine,</b>
<b>caffeine</b>); may inhibit metabolism and increase serum levels of <b>fosphenytoin,</b>
<b>phenytoin,</b>
<b>phenobarbital,</b>
<b>and primidone,</b>
<b>warfarin,</b>
<span class="classification">tricyclic antidepressants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 1.9 h; 47 h sustained release. <span class="typehead">Duration:</span> 36 h; 8 h sustained release. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP and pulse at appropriate intervals.</li>
<li>Lab tests: Obtain periodic CBC with differential and platelet counts during prolonged therapy.</li>
<li>Chronic abusive use can lead to tolerance, psychic dependence, and psychoses.</li>
<li>Assess patient's condition with periodic drug-free periods during prolonged therapy.</li>
<li>Supervise drug withdrawal carefully following prolonged use. Abrupt withdrawal may result in severe depression and psychotic
            behavior.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report adverse effects to physician, particularly nervousness and insomnia. These effects may diminish with time or require
            reduction of dosage or omission of afternoon or evening dose.
         </li>
<li>Check weight at least 2 or 3 times weekly and report weight loss. Check height and weight in children; failure to gain in
            either should be reported to physician.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>